A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FIB-4 / fibrosis-4

[Related PubMed/MEDLINE]
Total Number of Papers: 161
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FIB-4  (>> Co-occurring Abbreviation)
Long Form:   fibrosis-4
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Novel Diagnostic Nomogram for Noninvasive Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection. C-index, HBV, LSM, PLT, PT, ROC
2020 Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. AF, APRI, NAFLD, NASH CRN, NFS, T2D
2020 Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. AA, AST, NFS
2020 Accurate prediction of significant liver fibrosis using the Pentra score model in patients with chronic hepatitis C. APRI, CHC, GGT, HA, METAVIR, PLT, PTX3
2020 Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. CAP, HU, LHivPa, LIVEHIV, MHMC, NAFLD
2020 Assessing Non-Invasive Liver Function in Patients with Intestinal Failure Receiving Total Parenteral Nutrition-Results from the Prospective PNLiver Trial. IF, IFALD, NAFLD, PN, RPN, SPN
2020 Assessment of native liver fibrosis using ultrasound elastography and serological fibrosis indices in children with biliary atresia after the Kasai procedure. APRI, AUC, BA, LS, TE, US
2020 Associated Factors of Liver Disease After Fontan Operation in Relation to Ultrasound Liver Elastography. APRI, FALD, GGT
2020 Association between liver fibrosis and cognition in a nationally representative sample of older adults. CI
10  2020 Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy. ART, eGFR, Gal, VACS
11  2020 CD19+CD24hiCD38hi regulatory B cells: a potential immune predictive marker of severity and therapeutic responsiveness of hepatitis C. APRI, AST, DAA, HCV, TBILI
12  2020 Characteristics of regulatory T-cell function in patients with chronic hepatitis B and C coinfection. IFN, IL, TNF
13  2020 Correlation of the Fatty Liver Index with the Pathophysiological Abnormalities Associated with Cardiovascular Risk Markers in Japanese Men without any History of Cardiovascular Disease: Comparison with the Fibrosis-4 Score. baPWV, CVD, FLI
14  2020 Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. ICERs, MRE, NAFLD, VCTE
15  2020 Diagnostic Performance of Ultrasound Elastography and Serologic Fibrosis Indices for Evaluation of Hepatic Involvement in Wilson Disease. APRI, AUROC, SWE, TE, US, WD
16  2020 Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents? APRI, DAAs, EOT
17  2020 Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. APRI, DAAs, G/P, HCV, SVR
18  2020 Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. APRI, BMI, DAAs, HCV, HTD, IQR, RBV, SOF/DCV, SOF/LDV, SVR
19  2020 Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. APRI, AUROC, FS, HCV, LSM, SF, TE
20  2020 Evaluation of Fibrosis in Intestinal Failure-Associated Liver Disease in the Sustain Registry. CI, IF, IFALD, ORs, PN
21  2020 Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome. CAP, HIS, LAP, LFS, LSM, NAFLD, PCOS, TE
22  2020 Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples. ---
23  2020 Fibrosis-4 Index, a Noninvasive Fibrosis Marker, Predicts Survival Outcomes After Hepatectomy for Colorectal Cancer Liver Metastases. CRLM, OS, RFS
24  2020 Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score. HCRU, NAFLD/NASH
25  2020 Hepatitis C Testing and Liver Fibrosis Predictors in the Birth Cohort of a Primary Care Practice. ALT, APRI, HCV, OR
26  2020 Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study. CI, HCV, HR, HR, MC, RF
27  2020 Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. HFS, NFS, NLFS
28  2020 Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. AFP, ETV, HCC, NA
29  2020 Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage. ICH, PHE
30  2020 Liver fibrosis associated with potential vinyl chloride and ethylene dichloride exposure from the petrochemical industry. EDC, TDGA
31  2020 M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. CHC, DAAs, LSM, M2BPGi
32  2020 Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. AST, NAFL, NAFLD, NAS, NASH, NASH CRN, T2DM
33  2020 Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. ASCVD, NAFLD
34  2020 Noninvasive assessment of liver fibrosis in chronic hepatitis B carriers with sound touch elastography: study of surgical pathology specimens. APRI, CHB, GPR, LSMs, ROC, SSI, STE
35  2020 Relationship between platelet-based models and the prognosis of patients with malignant hepatic tumors. PLR, PLTs
36  2020 Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. AER, AST, CKD, CVD, EASL, FLI, NAFLD, NFS
37  2020 Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population. AUROC, M2BPGi, NPV, PPV
38  2020 Sex Differences, Cocaine Use, and Liver Fibrosis Among African Americans in the Miami Adult Studies on HIV Cohort. MASH, PLWH
39  2020 Stereotactic body radiation therapy planning for liver tumors using functional images from dual-energy computed tomography. DECT, F-VMAT, NID, Vfl
40  2020 Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. APRI, AUROC, BMI, SVR
41  2020 Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. AGA, ELF, HCC, NAFLD, NITs, PIVKA-II, US
42  2020 Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment. AST, BMI, HCV, PLT
43  2020 The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. APRI, AUC, CHB, CHI3L1, HCC, LC, LSM, ROC
44  2020 Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE. APRI, AUROC, GPR
45  2019 A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study. AUC, HBV, HCC, HR, RFS, TTV
46  2019 Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. AFLD, FLD, NAFLD
47  2019 Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans. ART, FABP, FASLG, HIV, MMP, sCD14, sCD163, VACS
48  2019 Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. FEP, FLI, NAFLD
49  2019 Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. APRI, CHB, CI, ETV, HBeAg
50  2019 Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction. AST/ALT, NAFLD
51  2019 CXCL12 G801A polymorphism is associated with significant liver fibrosis in HIV-infected Thais: a cross-sectional study. APRI, SNP
52  2019 Determination of liver fibrosis stages in Egyptian chronic hepatitis B patients by a noninvasive tool Angptl2, APRI, AUC, HBV, LF
53  2019 Diagnostic accuracy of different noninvasive scores for detecting advanced fibrosis in chronic hepatitis B. CHBI, GPR, NIS
54  2019 Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease. AIH, AILD, APRI, BMI, ElastPQ, PBC, pSWE
55  2019 Diagnostic performance of quantitative magnetic resonance imaging biomarkers for predicting portal hypertension in children and young adults with autoimmune liver disease. AILD, AST, AUROC, ROC
56  2019 Does fibrosis really regress in HIV/HCV co-infected patients after treatment with direct-antiviral agents? APRI, DAAs, EOT, LS, TE
57  2019 Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. HbA1c, NAFLD
58  2019 Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. APRI, NASH
59  2019 Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. DAAs, HCC, HCC, HCV, HR, LSM
60  2019 Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study. AUC, CHB, CI, GPR, HCC, HR, ROC
61  2019 High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. AUC, cBT, cFT, HOMA, MetS, NAFLD, SHBG, TT
62  2019 Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. AUC, LSM, NFS, NPV, PPV
63  2019 Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. DAA, HCC, HCV, SVR
64  2019 Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. NASH
65  2019 Liver Maximum Capacity: A Novel Test to Accurately Diagnose Different Stages of Liver Fibrosis. APRI, AST, CLD, LiMAx, TE
66  2019 Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. APRI, AUROC, HCV, LS
67  2019 Multiparametric CT for Noninvasive Staging of Hepatitis C Virus-Related Liver Fibrosis: Correlation With the Histopathologic Fibrosis Score. APRI, HCV, LSN
68  2019 New Algorithm for the Integration of Ultrasound Into Cystic Fibrosis Liver Disease Screening. APRI, AST, CFLD, GGT, US
69  2019 Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. CSVD, MBs, NAFLD, WMH
70  2019 Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. MRE, ROC
71  2019 Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. APRI, BMI, CACS, CVD, eGFR, NAFLD, NFS
72  2019 Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. AUROCs, ELF, LS by VCTE, NASH, NFS, NITs
73  2019 Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. APRI, NAFLD, NAS, NASH, PIIINP
74  2019 Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. AFP, CI, DAA, HCC, HR, SVR
75  2019 Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index. DAA, EOT, HCV, SVR
76  2019 Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease. HCV, QTc
77  2019 Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. HBV, HCC, HCV
78  2019 Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM. AHCVI, CI
79  2019 Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. APRI, NASH, NFS, OCA
80  2019 Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. AFP, APRI, CHC, HCC, miRNA, qRT-PCR
81  2019 Serum miR-21 correlates with the histological stage of chronic hepatitis B-associated liver fibrosis. AST, CHB
82  2019 The association between a non-invasive hepatic fibrosis score and urolithiasis among non-alcoholic fatty liver disease (NAFLD) patients in China: a cross-sectional study. NAFLD, ROC
83  2019 The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection. CHB, HCC, HR, OS, RFS
84  2019 TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. DAA, HCC, HCV, SVR, TLL1
85  2019 Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. APRI, AUROC, T2DM
86  2019 Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening. APRI, HBV, HCC, HCV
87  2019 Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients. CI, HR, LC, NAFLD
88  2019 Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan). ALT, API, APRI, AST, FCI, FibroScan, FIs, HCV, NFI
89  2019 Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. MTX, PLT, RA
90  2019 Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. APRI, AUROC, CHB, CI, OR
91  2018 A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. AFP, CHB, DM, ETV, HCC
92  2018 Acoustic Radiation Force Impulse Elastography with APRI and FIB-4 to Identify Significant Liver Fibrosis in Chronic Hepatitis B Patients. APRI, ARFI, CHB, CI
93  2018 Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. APRI, AVT, HCC, LS
94  2018 Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C. APRI, CHC, LS, SVR
95  2018 Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. APRI, CHC, EVs, M2BPGi
96  2018 Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. AJCC, ALBI, BCLC, HCC, PIS, RFS
97  2018 Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease. AST, AST/ALT, NAFLD, NFS
98  2018 Data Mining and Machine Learning Algorithms Using IL28B Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C. APRI, HCV, MLP, ROC
99  2018 Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. APRI, BCP
100  2018 Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. NAFLD, NASH